On September 11, 2020 Veracyte, Inc. (Nasdaq: VCYT) reported the initiation of a European study that will utilize the Delphi methodology to generate consensus regarding the clinical utility of genomic tests in breast cancer treatment (Press release, Veracyte, SEP 11, 2020, View Source [SID1234565020]). Led by an independent scientific committee of breast cancer experts with input from 180 breast cancer clinicians practicing in 12 European countries, the PROCURE study will explore and achieve consensus on the evidence supporting the most frequently used breast cancer multigene signatures (i.e., genomic tests).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As we’ve continued to learn more about how genomics impact treatment response and outcomes in breast cancer patients, genomic tests have become an invaluable tool for physicians," said Giuseppe Curigliano, MD, PhD, Istituto Europeo di Oncologia, Milan, and the PROCURE study coordinator. "However, there is not yet any consensus in the breast cancer community regarding the utility and ideal application of available tests, and this significantly complicates decision making. I’m excited to lead this study, which will generate this consensus using real-world insights and experiences from leading clinicians across Europe."
The Delphi method is a survey technique and established methodology for facilitating consensus on complex issues. The process includes at least two rounds of a structured questionnaire containing items to which participants express their degree of agreement. Consensus is reached by grouping participants’ responses after each successive wave of questioning. The PROCURE study will be conducted by Adelphi Targis, a medical research, education and communication agency with extensive experience using the Delphi methodology, and guided by an independent scientific committee led by Dr. Curigliano.
Over approximately 12 months, the study will gather input from participants to:
Comprehensively evaluate the existing evidence supporting the use of breast cancer genomic tests and the added value that clinicians attribute to them.
Assess the current and optimized use of these tools in patients with differing clinical-pathological profiles.
Establish recommendations on their use in routine clinical practice.
Discuss future clinical applications and research opportunities to facilitate a precision medicine approach in breast cancer.
Applying the rigorous Delphi process, the PROCURE scientific committee will use published clinical evidence along with participants’ input to establish and publish consensus recommendations for the use of genomic tests in clinical practice.
"PROCURE will provide much-needed guidance to breast cancer clinicians and their patients, helping them fully access the benefits offered by genomic testing," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "We’re grateful for the opportunity to sponsor this important study and to demonstrate our commitment to the global breast cancer community."